Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04324593
Other study ID # BXU544319
Secondary ID Pro00041143
Status Terminated
Phase N/A
First received
Last updated
Start date February 26, 2020
Est. completion date March 21, 2020

Study information

Verified date March 2021
Source Baxter Healthcare Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected. Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR. In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.


Recruitment information / eligibility

Status Terminated
Enrollment 26
Est. completion date March 21, 2020
Est. primary completion date March 21, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Has reviewed, understood and signed an informed consent. - Age between 18-55 years. - Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg. - Willing and able to comply with study procedures and duration. - Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission. Exclusion Criteria: - Female subjects who are pregnant. - Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days. - Subjects with known respiratory conditions including but not limited to: - uncontrolled / severe asthma - flu / influenza - pneumonia / bronchitis - shortness of breath / respiratory distress - respiratory or lung surgery - emphysema, chronic obstructive pulmonary disease, lung disease - any other health condition that the Principal Investigator thinks can affect respiratory health - Subjects with self-reported heart or cardiovascular conditions including but not limited to: - hypertension - history of cardiovascular surgery - chest pain (angina) - heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia - previous heart attack - blocked artery - unexplained shortness of breath - congestive heart failure - history of stroke - transient ischemic attack - carotid artery disease - myocardial ischemia - myocardial infarction - restrictive or constrictive cardiomyopathy - congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect - any type of cardiac valve disease - history of cardiac arrhythmias - Self-reported health conditions as identified in the Health Assessment Form - diabetes - uncontrolled thyroid disease - kidney disease / chronic renal impairment - history of seizures (except childhood febrile seizures) - epilepsy - history of unexplained syncope - history of migraine attacks in the last 3 months - head injury within the last 2 months - cancer / chemotherapy - other known health condition should be considered upon disclosure in health assessment form - history of substance abuse or addiction to alcohol and or drugs within the last 12 months - Subjects with self-reported bleeding disorders including but not limited to: - hemophilia - von Willebrand disease - history of blood clots - history of bleeding problems - bruises easily with everyday activities - Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine). - Subjects may be excluded at the discretion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Peripheral intravenous analysis (PIVA) algorithm
An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.

Locations

Country Name City State
United States Baxter Investigational Site Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Baxter Healthcare Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI. Score on the scale include 0=no signal, 1=poor signal, 2=good signal. The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position. End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)
Secondary Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases. End of 10 minute baseline
Secondary Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. End of 10 minute baseline
Secondary Agreement between PIVA algorithm-derived RR and RR measured with manual counting The manual count value will be an average of the 2 minutes then the count is taken over. The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. End of 10 minute baseline
Secondary Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. End of 10 minute baseline
Secondary Change in PIVA algorithm derived volume index between supine and passive leg raising positions The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum. End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
Secondary Change in PIVA algorithm derived volume index between supine and standing positions The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum. End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1